personalized treatment
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
personalized treatment
Jun 23, 2024, 18:54 |
Insight
Impact of Hormone Receptor Status in Young BRCA Carriers
Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X: .…
May 20, 2024, 14:10 |
Blog
Analysis of SCLC transcriptional factor subtypes finds differential CNS-specific outcomes - Memorial Sloan Kettering Radiation Oncology
Memorial Sloan Kettering Radiation Oncology made the following post on X: New by Dr. Kathryn…
May 16, 2024, 14:13 |
Opinion
Paolo Tarantino: A tremendous opportunity to validate the potential of HER2DX to predict outcomes in HER2+ BC
Paolo Tarantino made the following post on X: “HER2DX to Be Validated in Pivotal ECOG-ACRIN CompassHER2…
May 14, 2024, 07:15 |
Blog
Andrea Necchi: Optimizing the use of NGS in pts with urothelial carcinoma
Andrea Necchi, Associate Professor at Vita-Salute San Raffaele University, shared on X: “Optimizing the use…
Apr 2, 2024, 12:50 |
Blog
Antonio Passaro: Key milestones in cancer biomarker research and future avenues for enhancing the management of patients with solid tumors
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared a post on LinkedIn:…
Feb 11, 2024, 12:01 |
Insight
Vinay Mathew Thomas: Our viewpoint article on CheckMate 901 is now out in Med by Cell Press
Petros Grivas, Associate Professor at the University of Washington, shared an X post by Vinay…
Dec 11, 2023, 18:34 |
Insight
Yüksel Ürün: Mirvetuximab Soravtansine (MIRV) shows promise in platinum-resistant ovarian cancer
Yüksel Ürün, Medical Oncologist at Ankara University, shared on X/Twitter: ''Mirvetuximab Soravtansine (MIRV) shows promise…
All:
7
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube